好易升方防治中晚期食管癌同步放化疗骨髓抑制的临床疗效观察

Clinical Curative Observation of Haoyisheng Recipe on Preveting and Treating Myelosuppression Induced by Concomitant Radiotherapy and Chemotherapy for Advanced Esophageal Carcinoma

目的:观察好易升方预防中晚期食管癌同步放化疗所致骨髓抑制的近期临床疗效。方法:初治中晚期食管鳞癌患者80例随机分为治疗组和对照组。治疗组给予顺铂(25mg/m^2/d,d1~d3)+紫杉醇(135mg/m^2,d1)联合放疗方案,同时加用好易升方。对照组不使用中药,其余治疗均与治疗组相同。观察期为21天,分别对两组治疗第7天、14天、21天骨髓抑制发生情况进行分析,同时对两组治疗前后KPS评分、放射性食管炎、胃肠道反应、肝肾功能等指标进行观察。结果:两组均顺利完成放化疗。治疗组Ⅲ度及以上骨髓抑制及胃肠道反应发生率均低于对照组,差异有统计学意义(P<0.05)。治疗组的KPS评分提高率和对照组相比有统计学意义(P<0.05)。结论:好易升方能减少中晚期食管鳞癌同步放化疗Ⅲ度及以上骨髓抑制及胃肠道反应发生率,提高生活质量,且无肝肾功损害等不良反应。

Objective: To observe the short-term clinical effect of Haoyisheng Recipe on preventing the myelosuppression induced by concurrent chemoradiotheraphy for advanced esophageal carcinoma. Methods: Put 80non-surgical patients with advanced esophageal squamons cell carcinoma ( ESCC) randomly divided into treatment group and controlled group. The treatment group: 40cases with advanced ESCC were treated with cisplatin ( 25mg/m^2/d,d1~d3) and paclitaxel ( 135mg/m^2 ,d1) combined with radiotherapy. Meanwhile,the treatment group used Haoyisheng recipe. The controlled group: 40cases were treated with the same way besides Haoyisheng Recipe. The study was observed for 21days. The incidence of bone marrow suppression was analyzed on the 7th,14th and 21st day after treatment. KPS scores,radiation esophagitis,gastrointestinal reaction before and after the treatment were also analyzed. At the same time,liver function and kidney function were observed. Results: Both groups successfully completed the treatment plan. The incidence of myelosuppression ( grade≥3) and gastrointestinal reaction in the treatment group was significantly lower than that in the controlled group ( P<0. 05). The improvement rate of KPS scores in the treatment group was significantly higher than that in the controlled group ( P<0. 05). Conclusion: The Haoyisheng recipe can reduce the incidence of myelosuppression ( grade≥3) and gastrointestinal toxicity that caused by concurrent chemoradiotheraphy for advanced ESCC. It can improve the quality of life and have no adverse reactions such as liver and kidney dysfunction.